Literature DB >> 6244348

H-2 antigen requirements in the in vitro induction of SV40-specific cytotoxic T lymphocytes.

L R Gooding, C B Edwards.   

Abstract

T cytotoxic cells generated to syngeneic SV40 virus transformants lyse only SV40 target cells that are syngeneic at the H-2 locus. In contrast, SV40-specific tumor transplantation immunity shows no requirements for syngeneic H-2. Inoculation of allogeneic or even xenogeneic transformants will confer immunity to a challenge of syngeneic SV40 tumor cells. The experiments described here represent an attempt to reconcile these apparently conflicting observations. In our hands, generation of SV40-specific T cytotoxic cells in vitro requires both in vivo priming and secondary in vitro sensitization. We have found that priming for a secondary syngeneic-restricted response requires only that the cell employed be SV40 transformed. That is, priming may be accomplished with syngeneic, allogeneic, or xenogeneic SV40 transformants. Thus, the apparent lack of H-2 restriction in vivo immunity does not eliminate a role for the H-2-restricted cytotoxic T cell in tumor transplantation immunity.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6244348

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

Review 1.  Class I MHC presentation of exogenous antigens.

Authors:  C V Harding
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

2.  Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes.

Authors:  T M Fu; J B Ulmer; M J Caulfield; R R Deck; A Friedman; S Wang; X Liu; J J Donnelly; M A Liu
Journal:  Mol Med       Date:  1997-06       Impact factor: 6.354

3.  Constitutive class I-restricted exogenous presentation of self antigens in vivo.

Authors:  C Kurts; W R Heath; F R Carbone; J Allison; J F Miller; H Kosaka
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

4.  Fine mapping two distinct antigenic sites on simian virus 40 (SV40) T antigen reactive with SV40-specific cytotoxic T-cell clones by using SV40 deletion mutants.

Authors:  R W Anderson; M J Tevethia; D Kalderon; A E Smith; S S Tevethia
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

5.  Peptide-receptive class I major histocompatibility complex molecules on TAP-deficient and wild-type cells and their roles in the processing of exogenous antigens.

Authors:  R Song; A Porgador; C V Harding
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

6.  Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells.

Authors:  E Storozynsky; J G Woodward; J G Frelinger; E M Lord
Journal:  Immunology       Date:  1999-05       Impact factor: 7.397

7.  Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes.

Authors:  L M Mylin; T D Schell; D Roberts; M Epler; A Boesteanu; E J Collins; J A Frelinger; S Joyce; S S Tevethia
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model.

Authors:  T E Sparer; R A Tripp; D L Dillehay; T W Hermiston; W S Wold; L R Gooding
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

Review 9.  Heat shock proteins transfer peptides during antigen processing and CTL priming.

Authors:  P K Srivastava; H Udono; N E Blachere; Z Li
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

10.  Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells.

Authors:  B A Pulaski; K Y Yeh; N Shastri; K M Maltby; D P Penney; E M Lord; J G Frelinger
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.